Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2009 Apr 15;2009(2):CD004791.
doi: 10.1002/14651858.CD004791.pub2.

Antibiotic prophylaxis for spontaneous bacterial peritonitis in cirrhotic patients with ascites, without gastro-intestinal bleeding

Matan J Cohen  1 , Tali Sahar, Shmuel Benenson, Eran Elinav, Mayer Brezis, Karla Soares-Weiser
Affiliations
Meta-Analysis

Antibiotic prophylaxis for spontaneous bacterial peritonitis in cirrhotic patients with ascites, without gastro-intestinal bleeding

Matan J Cohen et al. Cochrane Database Syst Rev. .

Abstract

Background: Spontaneous bacterial peritonitis is frequent among cirrhotic patients, associated with significant morbidity and mortality. Selective intestinal decontamination employing antibiotics is a proposed prophylactic measure. While data regarding this modality among cirrhotic patients with gastrointestinal bleeding exist, there is insufficient data synthesis regarding cirrhotic patients with ascites and no gastrointestinal bleeding.

Objectives: To assess whether antibiotic prophylaxis decreases spontaneous bacterial peritonitis and mortality among cirrhotic patients with ascites and no gastrointestinal bleeding.

Search strategy: We identified relevant randomised trials by searching trial registries of The Cochrane Hepato-Biliary Group and The Cochrane Collaboration, medical literature search engines, and reviewing all literature we found on the topic until February 2009.

Selection criteria: We searched for randomised clinical trials assessing prophylactic treatment among adult cirrhotic patients with ascites and no gastrointestinal bleeding, comparing antibiotic therapy with no intervention, placebo, or with another antibiotic regimen.

Data collection and analysis: Three independent authors searched for and collected the trials and extracted relevant data. Four other independent authors validated the findings and assessed them. The studies were assessed for design, patient and intervention characteristics, and quality. A meta-analysis was performed to estimate measures of association between antibiotic prophylaxis and spontaneous bacterial peritonitis or mortality.

Main results: Nine trials were included in the review. Seven trials, comparing antibiotics to placebo or no treatment, were meta-analysed. Systematic bias in design or publication is suggested by trial results. The randomisation results suggest that the probability that true randomisation took place in all trials is very small and the report of most trials regarding design was poor. The proportion of participants with spontaneous bacterial peritonitis varied between the trials from 15% to 50%. The calculated relative risks (95% confidence interval) of spontaneous bacterial peritonitis and mortality among patients treated with antibiotics compared with no treatment/placebo were 0.20 (0.11 to 0.37) and 0.61 (0.43 to 0.87). There were very few reports of adverse events.

Authors' conclusions: The pooled estimates suggest that antibiotic prophylaxis might be prudent among cirrhotic patients with ascites and no gastrointestinal bleeding. However, poor trial methodology and report coupled with findings suggesting systematic bias in publication and design reflect the fragility of these findings. Potential hazard to society and the patients themselves from resistant pathogens should be considered when promoting long-lasting antibiotic prophylaxis. It seems that recommending antibiotic prophylaxis is still far from being a substantiated prevention strategy. Trials of better design, well reported, and of longer follow-up are greatly needed.

PubMed Disclaimer

Conflict of interest statement

None known.

Figures

1
1
Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
2
2
Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
3
3
Funnel plot of comparison: 1 Antibiotic prophylaxis versus placebo or no treatment, outcome: 1.1 SBP.
4
4
Funnel plot of comparison: 1 Antibiotic prophylaxis versus placebo or no treatment, outcome: 1.2 Mortality.
1.1
1.1. Analysis
Comparison 1 Antibiotic prophylaxis versus placebo or no treatment, Outcome 1 Spontaneous bacterial peritonitis.
1.2
1.2. Analysis
Comparison 1 Antibiotic prophylaxis versus placebo or no treatment, Outcome 2 Mortality.
1.3
1.3. Analysis
Comparison 1 Antibiotic prophylaxis versus placebo or no treatment, Outcome 3 All infections.
1.4
1.4. Analysis
Comparison 1 Antibiotic prophylaxis versus placebo or no treatment, Outcome 4 Adverse events.
1.5
1.5. Analysis
Comparison 1 Antibiotic prophylaxis versus placebo or no treatment, Outcome 5 Readmission.
2.1
2.1. Analysis
Comparison 2 Norfloxacin prophylaxis versus placebo or no treatment, Outcome 1 Spontaneous bacterial peritonitis.
2.2
2.2. Analysis
Comparison 2 Norfloxacin prophylaxis versus placebo or no treatment, Outcome 2 Mortality.
2.3
2.3. Analysis
Comparison 2 Norfloxacin prophylaxis versus placebo or no treatment, Outcome 3 All infections.
2.4
2.4. Analysis
Comparison 2 Norfloxacin prophylaxis versus placebo or no treatment, Outcome 4 Adverse events.
2.5
2.5. Analysis
Comparison 2 Norfloxacin prophylaxis versus placebo or no treatment, Outcome 5 Readmission.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD004791

References

References to studies included in this review

Alvarez 2005 {published and unpublished data}
    1. Alvarez RF, Mattos AA, Correa EB, Cotrim HP, Nascimento TV. Trimethoprim‐sulfamethoxazole versus norfloxacin in the prophylaxis of spontaneous bacterial peritonitis in cirrhosis. Arquivos de Gastroenterologia [Archives of Gastroenterology] 2005;42:256‐62. - PubMed
Bauer 2002 {published data only (unpublished sought but not used)}
    1. Bauer TM, Follo A, Navasa M, Vila J, Planas R, Clemente G, et al. Daily norfloxacin is more effective than weekly rufloxacin in prevention of spontaneous bacterial peritonitis recurrence. Digestive Diseases and Sciences 2002;47:1356‐61. - PubMed
Fernandez 2007 {published data only}
    1. Fernandez J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007;133:818‐24. - PubMed
Gines 1990 {published data only (unpublished sought but not used)}
    1. Gines P, Rimola A, Planas R, Vargas V, Marco F, Almela M, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double‐blind, placebo‐controlled trial. Hepatology 1990;12:716‐24. - PubMed
Grange 1998 {published data only (unpublished sought but not used)}
    1. Grange JD, Roulot D, Pelletier G, Pariente EA, Denis J, Ink O, et al. Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double‐blind randomized trial. Journal of Hepatology 1998;29:430‐6. - PubMed
Rolachon 1995 {published data only (unpublished sought but not used)}
    1. Rolachon A, Cordier L, Bacq Y, Nousbaum JB, Franza A, Paris JC, et al. Ciprofloxacin and long‐term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. Hepatology 1995;22:1171‐4. - PubMed
Singh 1995 {published data only (unpublished sought but not used)}
    1. Singh N, Gayowski T, Yu VL, Wagener MM. Trimethoprim‐sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis. Annals of Internal Medicine 1995;122:595‐8. - PubMed
Soriano 1991 {published data only (unpublished sought but not used)}
    1. Soriano G, Guarner C, Teixido M, Such J, Barrios J, Enriquez J, et al. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. Gastroenterology 1991;100:477‐81. - PubMed
Terg 2008 {published data only (unpublished sought but not used)}
    1. Terg R, Fassio E, Guevara M, Cartier M, Longo C, Lucero R, et al. Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: A randomized, placebo‐controlled study. Journal of Hepatology 2008;48:774‐9. - PubMed

References to studies excluded from this review

Novella 1997 {published data only}
    1. Novella M, Sola R, Soriano G, Andreu M, Gana J, Ortiz J, et al. Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin. Hepatology 1997;25:532‐6. - PubMed
Sandhu 2005 {published data only}
    1. Sandhu BS, Gupta R, Sharma J, Singh J, Murthy NS, Sarin SK. Norfloxacin and cisapride combination decreases the incidence of spontaneous bacterial peritonitis in cirrhotic ascites. Journal of Gastroenterology and Hepatology 2005;20:599‐605. - PubMed

Additional references

Andreu 1993
    1. Andreu M, Sola R, Sitges‐Serra A, Alia C, Gallen M, Vila MC, et al. Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. Gastroenterology 1993;104:1133‐8. - PubMed
Bernard 1995
    1. Bernard B, Cadranel JF, Valla D, Escolano S, Jarlier V, Opolon P. Prognostic significance of bacterial infection in bleeding cirrhotic patients: a prospective study. Gastroenterology 1995;108:1828‐34. - PubMed
Bernard 1998
    1. Bernard B, Grange JD, Khac EN, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with ascites: a meta‐analysis. Digestion 1998;59 Suppl 2:54‐7. - PubMed
Bernard 1999
    1. Bernard B, Grange JD, Khac EN, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: A meta‐analysis. Hepatology 1999;29:1655‐61. - PubMed
Bonten 2006
    1. Bonten MJM, Kreuger WA. Selective decontamination of the digestive tract: cumulating evidence, at last?. Seminars in Respiratory and Critical Care Medicine 2006;27:18‐22. - PubMed
Borzio 1997
    1. Borzio M, Salerno F, Saudelli M, Galvagno D, Piantoni L, Fragiacomo L. Efficacy of oral ciprofloxacin as selective intestinal decontaminant in cirrhosis.. Italian Journal of Gastroenterology and Hepatology 1997;29(3):262‐6. - PubMed
Campillo 1998
    1. Campillo B, Dupeyron C, Richardet JP, Mangeney N, Leluan G. Epidemiology of severe hospital‐acquired infections in patients with liver cirrhosis: effect of long‐term administration of norfloxacin. Clinical Infectious Diseases 1998;26(5):1066‐70. - PubMed
Chavez‐Tapia 2009
    1. Chavez‐Tapia NC, Soares‐Weiser K, Brezis M, Leibovici L. Antibiotics for spontaneous bacterial peritonitis in cirrhotic patients. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858] - DOI - PMC - PubMed
Das 1998
    1. Das A. A cost analysis of long term antibiotic prophylaxis for spontaneous bacterial peritonitis in cirrhosis. American Journal of Gastroenterology 1998;93:1895‐900. - PubMed
de Jonge 2003
    1. Jonge E, Schultz MJ, Spanjaard L, Bossuyt PMM, Vroom MB, Dankert J, et al. Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial. Lancet 2003;362:1011‐6. - PubMed
de Jonge 2005
    1. Jonge E. Effects of selective decontamination of digestive tract on mortality and antibiotic resistance in the intensive‐care unit. Current Opinion in Critical Care 2005;11:144‐9. - PubMed
Egger 1997
    1. Egger M, Davey‐Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.) 1997;315:629‐34. - PMC - PubMed
File 2007
    1. File TM. Hospital‐acquired (nosocomial) pneumonia in adults. In: Rose BD editor(s). UpToDate. Waltham, MA, 2007.
Follo 1994
    1. Follo A, Llovet JM, Navasa M, Planas R, Forns X, Francitorra A, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994;20:1495‐501. - PubMed
Garcia‐Tsao 1995
    1. Garcia‐Tsao G, Lee FY, Barden GE, Cartun R, West AB. Bacterial translocation to mesenteric lymph nodes is increased in cirrhotic rats with ascites. Gastroenterology 1995;108:1835‐41. - PubMed
Gluud 2009
    1. Gluud C, Nikolova D, Klingenberg SL, Whitfield K, Alexakis N, Als‐Nielsen and the Cochrane Hepato‐Biliary Group. About The Cochrane Collaboration. Cochrane Review Groups (CRGs) 2009; Vol. 1.
Hedges 1985
    1. Hedges LV, Olkin I. Statistical methods for meta‐analysis. Orlando: Academic Press, 1985.
Inadomi 1997
    1. Inadomi J, Sonnenberg A. Cost‐analysis of prophylactic antibiotics in spontaneous bacterial peritonitis. Gastroenterology 1997;113:1289‐94. - PubMed
Iyengar 1988
    1. Iyengar S, Greenhouse JB. Selection models and the file drawer problem. Statistical Science 1988;3:109‐17.
Kjaergard 2001
    1. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine 2001;135:982‐9. - PubMed
Llovet 1997
    1. Llovet JM, Rodriguez Iglesias P, Moitinho E, Planas R, Bataller R, Navasa M, et al. Spontaneous bacterial peritonitis in patients with cirrhosis undergoing selective intestinal decontamination. A retrospective study of 229 spontaneous bacterial peritonitis episodes. Journal Hepatology 1997;26(1):88‐95. - PubMed
Moher 1998
    1. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet 1998;352:609‐13. - PubMed
Mowat 2001
    1. Mowat C, Stanley AJ. Spontaneous bacterial peritonitis ‐ diagnosis, treatment and prevention. Alimentary Pharmacology & Therapeutics 2001;15:1851‐9. - PubMed
NCCLS 2007
    1. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing. Wayne, PA, USA: NCCLS, 2007.
Ortiz 1999
    1. Ortiz J, Vila MC, Soriano G, Minana J, Gana J, Mirelis B, et al. Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients. Hepatology 1999;29(4):1064‐9. - PubMed
Orwin 1983
    1. Orwin R. A fail‐safe N for effect size in meta‐analyses. Journal of Educational Statistics 1983;8:157‐9.
Persaud 1996
    1. Parsaud R. Misleading meta‐analysis. "Fail safe N" is a useful mathematical measure of the stability of results. BMJ (Clinical Research Ed.) 1996;312:125. - PMC - PubMed
Rimola 2000
    1. Rimola A, Garcia‐Tsao G, Navasa M, Piddock LJV, Planas R, Bernard B, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. Journal of Hepatology 2000;32:142‐53. - PubMed
Runyon 1986
    1. Runyon BA. Low‐protein‐concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. Gastroenterology 1986;15:1343‐8. - PubMed
Runyon 1988
    1. Runyon BA. Spontaneous bacterial peritonitis: an explosion of information. Hepatology 1988;8:171‐5. - PubMed
Runyon 1994
    1. Runyon BA, Squier S, Borzio M. Translocation of gut bacteria in rats with cirrhosis to mesenteric lymph nodes partially explains the pathogenesis of spontaneous bacterial peritonitis. Journal of Hepatology 1994;21:792‐6. - PubMed
Schulz 1995
    1. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. dimensions of methodological quality associated with estimates of treatment effects in controlled trials. The Journal of the American Medical Association 1995;273:408‐12. - PubMed
Siegel 1988
    1. Siegel S, Castellan NJ Jr. Nonparametric statistics for the behavioural sciences. 2nd Edition. New York: McGraw Hill International, 1988.
Silvestri 2006
    1. Silvesteri L, Petros A, Viviani M, Rommes JH, Saene HKF. Selective decontamination of the digestive tract and ventilator‐associated pneumonia. Respiratory Care 2006;51:67‐8. - PubMed
Soares‐Weiser 2002
    1. Soares‐Weiser K, Brezis M, Tur‐Kaspa R, Leibovici L. Antibiotic prophylaxis for cirrhotic patients with gastrointestinal bleeding. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI: 10.1002/14651858.CD002907] - DOI - PubMed
Soares‐Weiser 2003
    1. Soares‐Weiser K, Brezis M, Tur‐Kaspa R, Paul M, Yahav J, Leibovici L. Antibiotic prophylaxis of bacterial infections in cirrhotic inpatients: a meta‐analysis of randomized controlled trials. Scandinavian Journal of Gastroenterology 2003;38(2):193‐200. - PubMed
Soriano 1989
    1. Soriano G, Teixido M, Guarner C, Such J, Espinos JC, Sainz S. Variation of C3 in ascitic fluid from cirrhotic patients subjected to intestinal sterilization or selective intestinal decontamination. Revista Espanola de Enfermedades Digestivas 1989;75(2):123‐6. - PubMed
Soriano 1992
    1. Soriano G, Guarner C, Tomas A, Anguera A, Mirelis B, Fernandez C, et al. The duration of the effect of norfloxacin on the fecal flora in cirrhosis patients. Revista Espanola de Enfermedades Digestivas 1992;81(5):322‐6. - PubMed
Stoutenbeek 2007
    1. Stoutenbeek CP, Saene HKF, Little RA, Whitehead A, and the Working Group on Selective Decontamination of the Digestive Tract. The effect of selective decontamination of the digestive tract on mortality in multiple trauma patients: a multicenter randomized controlled trial. Intensive Care Medicine 2007;33:261‐70. - PubMed
Thadepalli 1990
    1. Thadepalli H, Lou MA, Prabhala RH, Mandal AK. Human intestinal tissue antibiotic concentrations. Clindamycin, gentamicin, and mezlocillin. The American Surgeon 1990;56(11):655‐8. - PubMed
Tito 1988
    1. Tito L, Rimola A, Gines P, Llach J, Arroyo, Rodes J. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology 1988;8:27‐31. - PubMed
Toledo 1993
    1. Toledo C, Salmeron JM, Rimola A, Navasa M, Arroyo V, Llach J, et al. Spontaneous bacterial peritonitis in cirrhosis: predictive factors of infection resolution and survival in patients treated with cefotaxime. Hepatology 1993;17:251‐7. - PubMed
Tomas 1991
    1. Tomas A, Soriano G, Guarner C, Teixido M, Mendez C, Tena F, et al. An analysis of hospital bacterial infections in cirrhotic patients undergoing selective intestinal decontamination. Revista Espanola de Enfermedades Digestivas 1991;79(4):259‐64. - PubMed
Trifilio 2004
    1. Trifilio S, Verma A, Mehta J. Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: heterogeneity of current clinical practice. Bone Marrow Transplantion 2004;33:735‐9. - PubMed
van Belkum 2005
    1. Belkum A, Vos MC. Prophylactic application of fluoroquinolones for selective decontamination of the gut: friend or foe. European Journal of Clinical Microbiology and Infectious Diseases 2005;24:109‐10. - PubMed
Wood 2008
    1. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ (Clinical Research Ed.) 2008;336:601‐5. - PMC - PubMed
Younossi 1997
    1. Younossi ZM, McHutchison JG, Ganiats TG. An economic analysis of norfloxacin prophylaxis against spontaneous bacterial peritonitis. Journal of Hepatology 1997;27:295‐8. - PubMed
Zar 1998
    1. Zar JH. Biostatistical Analysis. 4th Edition. Prentiss Hall, 1998.

MeSH terms

LinkOut - more resources